Vascular endothelial growth factor and interleukin-6 in paracrine tumor- stromal cell interactions in multiple myeloma

Blood

Volumn 95, Issue 8, 2000, Pages 2630-2636

  Dankbar, Berno ^a   Padró, Teresa ^a   Leo, Regine ^a   Feldmann, Birgit ^a   Kropff, Martin ^a   Mesters, Rolf M ^a   Serve, Hubert ^a   Berdel, Wolfgang E ^a   Kienast, Joachim ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ARTICLE; CELL INTERACTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STROMA CELL; TUMOR VASCULARIZATION;

EID: 0034655957     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.8.2630     Document Type: Article

References (58)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med. 1997;336:1657.
2. Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73:517.
3. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and essential requirement of BSF-2/ IL-6 for human multiple myeloma. Nature. 1988; 332:83.
4. Klein B, Bataille R. Cytokine network in human multiple myeloma. Hematol Oncol Clin North Am. 1992;6:273.
5. Anderson KC, Jones RM, Morimoto C, Leavitt P, Barut BA. Response pattern of purified myeloma cells to hematopoietic growth factors. Blood. 1989;73:1915.
6. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995; 85:863.
7. Nachbaur DM, Herold M, Maneschg A, Huber H. Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. Ann Hematol. 1991;62:54.
8. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin-6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989;84: 2008.
9. Kyrstsonis MC, Dedoussis G, Baxevanis C, Stamatelou M, Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM). Br J Haematol. 1996;92:420.
10. Zhang XG, Bataille R, Widjenes J, Klein B. Interleukin-6 dependence of advanced malignant plasma cell dyscrasias. Cancer. 1992;69:1373.
11. Hardin J, MacLeod S, Grigorieva I, et al. Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994;84:3063.
12. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248.
13. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227.
14. Grigorieva I, Thomas X, Epstein J. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp Hematol. 1998;26:597.
15. Hallek M, Bergsagel PL, Anderson KC. Multiple myeloma: increasing evidence for a multistep transformation process. Blood. 1998;91:3.
16. Urashima M, Chen BP, Chen S, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood. 1997; 90:754.
17. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood. 1993; 82:3712.
18. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87:1104.
19. Lokhorst HM, Lamme T, de Smet M, et al. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994;84:2269.
20. Kim I, Uchiyama H, Chauhan D, Anderson KC. Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines. Br J Haematol. 1994;87: 483.
21. Thomas X, Anglaret B, Magaud JP, Epstein J, Archimbaud E. Interdependence between cytokines and cell adhesion molecules to induce interleukin-6 production by stromal cells in myeloma. Leuk Lymphoma. 1998;32:107.
22. Carter A, Merchav S, Silvian-Draxler I, Tatarsky I. The role of interleukin-1 and tumor necrosis factor-alpha in human multiple myeloma. Br J Haematol. 1990;74:424.
23. Shalaby MR, Waage A, Espevik T. Cytokine regulation of interleukin-6 production by human endothelial cells. Cell Immunol. 1989;121:372.
24. Urashima M, Ogata A, Chauhan D, et al. Transforming growth factor-β1: differential effects on multiple myeloma versus normal B cells. Blood. 1996;87:1928.
25. Claffey KP, Robinson GS. Regulation of VEGF/ VPF expression in tumor cells: consequences foi tumor growth and metastasis. Cancer Metast Rev. 1996;15:165.
26. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med. 1995;1:27.
27. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185.
28. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603.
29. Weidner N, Semple P, Welch W, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med. 1991; 324:1.
30. Plate KH. Vascular endothelial growth factor and glioma angiogenesis: coordinate induction of VEGF receptors, distribution of VEGF protein and possible in vivo regulatory mechanisms. Int J Cancer. 1994;59:520.
31. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993; 362:841.
32. Claffey KP, Brown LF, del Aguila LF, et al. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996;56: 172.
33. Vacca A, Ribatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503.
34. Vacca A, Di Loreto M, Ribatti D, et al. Bone marrow of patients with active multiple myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1 and CD44. Am J Hematol. 1995;50:9.
35. Munshi N, Wilson CS, Penn J, et al. Angiogenesis in newly diagnosed multiple myeloma: poor prognosis with increased microvessel density (MVD) in bone marrow biopsies [abstract]. Blood. 1998; 92:98a.
36. Dankbar B, Padró T, Mesters RM, et al. VEGF is expressed by myeloma cells and stimulates IL-6 secretion by microvascular endothelial and marrow stromal cells [abstract]. Blood. 1998;92:681a.
37. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res. 1999;59:728.
38. Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064.
39. Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Cancer. 1975;36:842.
40. Lagneaux L, Delforge A, Dorval C, Bron D, Stryckmans P. Excessive production of transforming growth factor-β by bone marrow stromal cells in B-cell chronic lymphocytic leukemia inhibits growth of hematopoietic precursors and interleukin-6 production. Blood. 1993;82:2379.
41. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987;162:156.
42. Fiedler W, Graeven U, Ergün S, et al. Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood. 1997;89:1870.
43. Krüssel JS, Casan EM, Raga F, et al. Expression of mRNA for vascular endothelial growth factor transmembraneous receptors FLT1 and KDR, and the soluble receptor sflt in cycling human endometrium. Mol Hum Reprod. 1999;5:452.
44. Siegel S, Castellan JN. Nonparametric Statistics for the Behavioral Science. Singapore, McGraw-Hill Book Co; 1988:190.
45. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model tor studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92:2908.
46. Vacca A, Ribatti D, Iurlaro M, et al. Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. Int J Clin Lab Res. 1998;28:55.
47. Cornali E, Zietz C, Benelli R, et al. Vascular endothelial growth factor regulates angiogenesis and vascular permeability in Kaposi's sarcoma. Am J Pathol. 1996;149:1851.
48. Brock TA, Dvorak HF, Senger DR. Tumor-secreted vascular permeability factor increases cytosolic Ca2+ and von Willebrand factor release in human endothelial cells. Am J Pathol. 1991;138: 213.
49. Connolly DT, Olander JV, Heuvelman D, et al. Human vascular permeability factor: isolation from U937 cells. J Biol Chem. 1989;264:20,017.
50. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for endothelial cell growth factor. Biochem Biophys Res Commun. 1992;187:1579.
51. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene. 1990;5:519.
52. De Vries C, Escobedo JA, Ueno H, Houck KA, Ferrara N. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science. 1992;255:989.
53. Caligaris-Cappio F, Bergui L, Gregoretti MG, et al. Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood. 1991; 77:2688.
54. Rafii S, Shapiro F, Rimarachin J, et al. Isolation and characterization of human bone marrow microvascular endothelial cells: hematopoietic progenitor cell adhesion. Blood. 1994;84:10.
55. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem. 1996;271:736.
56. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood. 1999;93:4034.
57. Barut BA, Zon LI, Cochran MK, et al. Role of interleukin 6 in the growth of myeloma-derived cell lines. Leukemia Res. 1992;16:951.
58. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9.